Oncology Institute (TOIIW) Receivables (2020 - 2026)

Oncology Institute (TOIIW) has reported Receivables for 7 consecutive years, with $59.4 million the latest figure, recorded in Q1 2026.

• Receivables for Q1 2026 came in at $59.4 million, up 19.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.4 million (up 19.7% YoY), and the FY2025 annual result was $59.3 million, up 21.85% from the prior year.
• Receivables was $59.4 million for Q1 2026 at Oncology Institute, roughly flat from $59.3 million in the prior quarter.
• Over five years, Receivables peaked at $60.0 million in Q3 2025 and troughed at $25.8 million in Q1 2022.
• Average Receivables over 5 years is $48.1 million, with a median of $48.9 million recorded in 2023.
• Year-over-year, Receivables jumped 90.33% in 2022 and slipped 16.0% in 2025.
• Over 5 years, Receivables stood at $40.4 million in 2022, then grew by 6.13% to $42.9 million in 2023, then advanced by 13.45% to $48.7 million in 2024, then gained by 21.85% to $59.3 million in 2025, then climbed by 0.22% to $59.4 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $59.4 million in Q1 2026, $59.3 million in Q4 2025, and $60.0 million in Q3 2025.